Loading page
Loading page
Loading substance route
Different salt forms (hydrochloride, succinate, fumarate) exhibit varying potencies by weight and bulk density.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Moderately addictive with high potential for abuse, capable of causing psychological dependence in some users. Compulsive redosing can occur due to euphoric effects, though this urge is often reported as less pressing than with MDMA due to the longer duration.
Cravings and withdrawal effects may occur when chronic use is suddenly stopped. After-effects including depression, irritability, and cognitive fatigue for several days following use are commonly reported, attributed to neurotransmitter depletion rather than true physical dependence.
The exact toxic dosage is unknown. Common doses do not appear acutely dangerous for healthy individuals, though overdoses can occur and may feature paranoia, anxiety, headache, agitation, and hypertension.
Long-term or chronic use involving regular daily or weekly dosing is likely cardiotoxic and may lead to valvulopathy; occasional recreational use at typical doses carries significantly lower risk.
Repeated or high-dose administration may result in neurotoxicity presenting as deficits in cognitive, affective, and psychomotor function, though 6-APB was specifically designed to be less neurotoxic than MDA or MDMA and single responsible uses are likely physically safe.
Acute psychosis has been reported in combination with synthetic cannabinoids. Delusions are listed among possible cognitive effects, typically at higher doses or during the offset phase of the experience.
Rare effect primarily occurring in predisposed individuals, particularly when taking high doses or redosing while dehydrated, fatigued, undernourished, or overheated.
The benzofuran entactogens emerged from academic research into the structure-activity relationships of MDMA and related compounds. In 1993, medicinal chemist David E. Nichols and colleagues at Purdue University investigated 5-APDB and 6-APDB as serotonin releasing agents and entactogens, examining…
May be considered a controlled substance under 'substantially similar' catch-all provisions in Australian drug law due to structural similarity to MDA, which is a controlled substance.
Listed as a controlled substance since July 1, 2024.
Listed in the government decree on narcotic substances, preparations and plants. Possession and distribution are illegal.
Added to Anlage II of the Betäubungsmittelgesetz (Narcotics Act) on July 17, 2013. Manufacturing, possession, import, export, purchase, sale, procurement, or dispensing without a license is prohibited.
Designated as a controlled substance effective December 17, 2012.
Banned under the Opium Law as of July 1, 2025 following an amendment addressing New Psychoactive Substances. This structural ban covers phenethylamine-based compounds including cathinones and amphetamines.
Listed as a controlled substance since April 17, 2013 under Decreto-Lei n.º 54/2013.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Initially classified as a Temporary Class Drug on June 10, 2013 following an ACMD recommendation. On June 10, 2014, it became a permanent Class B, Schedule 1 substance alongside all other benzofuran entactogens and structurally related compounds.
Legal status remains uncertain. A 2014 study funded by the Canadian Institutes of Health Research noted it 'may or may not be legal' depending on interpretation of the Controlled Drugs and Substances Act. While structurally similar to MDA, its benzofuran structure does not make it a direct amphetamine analogue.
Listed under Nařízení vlády č. 463/2013 Sb. Use is permitted for research and restricted therapeutic purposes only.
Classified as a narcotic substance since May 9, 2018, alongside other benzofuran derivatives.
Classified as a controlled substance. Possession, production, and distribution are prohibited.
Not listed among prohibited substances under national drug legislation as of available information.
May be viewed as a controlled substance analogue under catch-all provisions due to chemical structure similarities to MDA.
Initially classified as a 'health hazard' under the Act on the Prohibition of Certain Goods Dangerous to Health on December 27, 2009. Subsequently reclassified as a narcotic substance in 2020.
Classified as a controlled drug. Possession, production, supply, and import are prohibited.
Not scheduled at the federal level. However, it may be considered an analogue of MDA, meaning purchase, sale, or possession with intent to consume could potentially be prosecuted under the Federal Analogue Act. Several states have independently scheduled it: Florida and Louisiana list it as Schedule I (2013), Minnesota added it to Schedule I in 2012, and Wisconsin classified it as Schedule I in 2018.
15 sources cited
